Related Experiment Video

Updated: Aug 16, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Cardiac glycosides in complex treatment of patients with heart failure and supraventricular arrhythmias]

Iu N Zamotaev, Iu A Kremnev, S E Podshibiakin

    Klinicheskaia Meditsina
    |August 25, 2005
    PubMed

    Insights

    Celanide, enalapril, and indapamide effectively treated heart failure (HF) and supraventricular arrhythmias. This combination improved patient hemodynamics, activity tolerance, and quality of life at a lower cost.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Heart failure (HF) and supraventricular arrhythmias are common cardiovascular conditions.
    • Effective treatment strategies are crucial for improving patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy of two drug combinations in patients with heart failure and supraventricular arrhythmias.
    • To compare the effectiveness of atenolol + enalapril + indapamide versus celanide + enalapril + indapamide.

    Main Methods:

    • A study involving 106 patients with varying degrees of heart failure (NYHA FC II-III) and supraventricular arrhythmias.
    • Patients were divided into two groups receiving different drug combinations for two months.
    • Key parameters assessed included hemodynamics, activity tolerance, and quality of life.

    Main Results:

    • Both treatment regimens led to improvements in hemodynamics, increased activity tolerance, and enhanced quality of life.
    • The combination of celanide + enalapril + indapamide demonstrated significant effectiveness in managing FC II-III HF with supraventricular arrhythmias.
    • Treatment with celanide was associated with lower costs.

    Conclusions:

    • The drug combination of celanide + enalapril + indapamide is an effective therapeutic option for patients with heart failure and supraventricular arrhythmias.
    • This combination offers a cost-effective alternative for managing these complex cardiovascular conditions.

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Dysrhythmias VI: Management of Dysrhythmias01:25

    Dysrhythmias VI: Management of Dysrhythmias

    Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...